TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Post Marketing Observational Study on Paricalcitol IV Administered to Venezuelan Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 18 years old with documented diagnosis of stage V chronic kidney disease, on hemodialysis at study baseline~* Subjects who have been previously treated with vitamin D or its metabolites or naïve to paricalcitol~* Subjects in whom the use of paricalcitol is clinically indicated and documented by applicable and routine standard of healthcare (i.e. laboratory assessments and clinical evaluations) according to the criteria of the attending physician and in accordance with the approved label of the product in Venezuela~* Subjects that provide written informed consent form stating his/her authorization and willingness to participate in the study and allowing the use and discussion of his/her personal and/or health information before entering the study~* Female subjects with reproductive potential must use an approved contraceptive method (intrauterine device, birth control pills or barrier device) during and for three (03) months after discontinuation of treatment~Exclusion Criteria:~* Subjects with severe hyperparathyroidism (parathyroid hormone \[PTH\] \> 3000 pg/mL)~* Subjects with hypercalcemia, adjusted according to serum albumin, hyperphosphatemia, or subjects with calcium-phosphorus product (Ca x P) ≥ 70~* Known hypersensitivity and/or toxicity of vitamin D, its metabolites and/or other components of Zemplar® IV (paricalcitol)~* Subjects who have participated in clinical trials within 30 days before the start of the study or who are currently enrolled in a clinical trial or under treatment with any investigational product~* Subjects who cannot tolerate or cannot take phosphate binders that do not contain calcium and/or aluminum~* Subjects who in the opinion of the investigator, for any reason (including medical reasons) are not eligible and/or appropriate for therapy with synthetic analogs of vitamin D and/or unwilling to complete the study visits

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paricalcitol IV (Type: None): Eligible participants with diagnosis of chronic kidney disease stage V undergoing hemodialysis, treated with paricalcitol IV per routine clinical practice according to prescribing information approved in Venezuela and clinical criteria.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Caffeine Reduction and Anticholinergic Medications for Treatment of Overactive Bladder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Women with OAB symptoms including urgency, frequency (voids ≥8/day), and urge incontinence~2. Women who consume \> one cup (250ml) caffeinated beverage per day~3. Women who score $ 6 on the QUID Questionnaire for urgency symptoms~Exclusion Criteria:~1. Women currently receiving treatment for OAB symptoms~2. Women with narrow angle Glaucoma~3. Women taking anticholinergics or loop diuretics~4. Women with an untreated urinary tract infection. After resolution of the UTI, and if all other eligibility criteria are met, the woman can be a candidate for inclusion in the study.~5. Women with a diagnosis of painful bladder syndrome or other abnormal urinary tract lesions~6. Women scoring \>4 on the QUID Questionnaire for stress symptoms~7. Women with de novo symptoms following surgery~8. Women with major pelvic prolapse

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Caffeine reduction through diet and beverage counselling
- 2 (Type: ACTIVE_COMPARATOR): Anticholinergic medication

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cholecalciferol and Flu Vaccine in Treating Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy individuals seen at the Employee Health Clinic who will be eligible to receive influenza vaccine~* Willingness to comply with study expectations~* subject or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure~* INTERVENTION COMPONENT ONLY:~* Willing to suspend use of any other vitamin D supplementation during the 3 month treatment interval; if currently using \> 2,000 IU/day of vitamin D supplementation, must suspend use 30 days prior to enrollment~Exclusion criteria:~-not RPCI employee

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Arm I (400 IU cholecalciferol and vaccine therapy) (Type: EXPERIMENTAL): Patients receive low-dose cholecalciferol PO QD for 12 weeks, followed by the seasonal (2012-2013) trivalent influenza vaccine IM.
- Arm II (4,000 IU cholecalciferol and vaccine therapy) (Type: EXPERIMENTAL): Patients receive high-dose cholecalciferol PO QD for 12 weeks, followed by the seasonal (2012-2013) trivalent influenza vaccine IM.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Body Position and Probe Position on the Localization of Breast Mass

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Female~2. 21-70 years of age~3. Known palpable or non-palpable benign or probably benign breast mass or masses, less than 2 cm in maximum diameter and at least 4 cm away from the nipple, from a previous ultrasound examination~Exclusion Criteria:~1. Women with cardiac pacemaker or portable defibrillator~2. Women with known breast cancer or suspicious lesions~3. Pregnant and lactating women~4. Women who have breast implant(s)~5. Women who have had prior breast surgical intervention not including breast needle biopsy, in the same breast with the qualifying target mass.~6. Women with the target finding to be mapped within a distance of 4 cm from patient's nipple.~7. Women with multiple similar qualifying targets in close proximity (less than 4 cm between targets).~8. Women with history of allergy to medical-grade adhesive tape or ultrasound gel~9. Women whose weight is over 250 pounds

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- female breast ultrasound exam (Type: None): females with at least one benign or probably benign mass, up to 2 cm in size, in one breast, detected during a standard-of-care breast ultrasound examination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study to Predict the Response of Erythropoietin Treatment in Participants With Cancer Related Anemia Receiving Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants with non-hematologic malignancy (cancer or other progressively enlarging and spreading tumor, usually fatal if not successfully treated)~* Participants with life expectancy of at least 6 months based on the Investigator's clinical judgment~* Participants receiving chemotherapy~* Participants having indication and planning to receiving erythropoietin (dosage and regimen should comply with Thai FDA approval package insert)~* Participants who have given consent form~Exclusion Criteria:~* Participants with anemia due to other factors (i.e., iron, B12 or folate deficiencies, hemolysis \[breakdown in red blood cells\], gastrointestinal bleeding, or any active bleeding)~* Participants with previous history of erythropoietin treatment~* Participants who have received blood transfusion within 1 month before starting erythropoietin therapy~* Pregnant or breast-feeding female participants

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Participants with cancer related anemia (Type: None): Participants with cancer related anemia receiving chemotherapy will be observed for response to erythropoietin treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk AML and MDS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with refractory AML Refractory AML is defined as follows;~  1. Primary refractory: failure to achieve complete remission (CR) after 2 cycles of induction chemotherapy; or, in patient ≥65 years of age, progressive AML after treatment with hypomethylating agent (increase in peripheral blood blast by 50% or increase in bone marrow blast by 25%)~ 2. Relapse then refractory: recurrence of AML, which is refractory to standard salvage chemo therapy; or, in patient ≥65 years of age, to hypomethylating agent~ 3. AML in ≥2 relapses~* Patients should be 19 years of age or older~* Patients should have Karnofsky performance scale ≥70~* Patients and cell donors must understand fully and sign informed consent forms~Exclusion Criteria:~* Pregnant or lactating women~* Patient with abnormal liver function (total bilirubin ≥ 5.0 mg/dl, AST ≥ 5 times upper normal limits)~* Patients with abnormal renal function (creatinine ≥ 3.0 mg/dl)~* Patients with clinically-evident cardiac or pulmonary dysfunction~* Patients with infection that is progressive despite appropriate anti-microbial treatment~* Patients with hypersensitivity to gentamicin~* Patients who had received allogeneic cell therapy previously.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- treatment (Type: EXPERIMENTAL): patients will receive donor-derived NK cell infusion after haploidentical HCT
- control (Type: NO_INTERVENTION): patients will undergo haploidentical HCT but not receive donor-derived NK cells after HCT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Renal Sarcoidosis by Methylprednisolone Bolus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Acute kidney injury with estimated glomerular filtration rate (eGFR) \< 60 mL/min/1,73 m2, defined by an increase of initial value \> 25% or an increase of \> 30 µmol/l, since at least 3 months.~* Sarcoidosis diagnostic criteria according to ATS/ERS/WASOG (Am J Respir Crit Care Med 1999)~* Renal biopsy compatible with renal sarcoidosis :~* Granulomatosis tubulo-interstitial nephropathy and extra-renal damage of histologically proved or suggestive sarcoidosis Or~* Tubulo-interstitial nephropathy without granuloma and extra-renal damage of histologically proved sarcoidosis~* Informed consent~* Patients with social security~Exclusion Criteria:~* Corticosteroids greater than 0,25 mg/kg/j prednisone equivalent~* Introduction of an immunosuppressant in the month before inclusion~* Another cause of renal granulomatosis or tubulo-interstitial nephropathy~* Isolated renal damage without extra-renal past or present damage for a sarcoidosis~* Chronic renal failure, prior sarcoidosis with eGFR \< 30 mL/min/1,73 m2~* Acute renal failure from other causes. If hypercalcaemia is greater than 3 mmol/L, the correction of any dehydration will systematically salt intake, followed of renal function control before inclusion.~* Pregnancy, nursing~* Tuberculosis~* Uncontrolled sepsis~* Uncontrolled psychotic state~* Hypersensibility to methylprednisolone hemisuccinate~* Drugs prescription causing wave burst arrhythmia and/or long QT on ECG

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- oral prednisone (Type: NO_INTERVENTION): Oral prednisone 1 mg/kg/d for 30 days and progressive tapering of steroids, to get 0,5 mg/kg/d at M3 and 0,25 mg/kg/d at M6 and 5-10 mg at M12.
- methylprednisolone bolus (Type: EXPERIMENTAL): methylprednisolone bolus 15 mg/kg/d for 3 days before oral prednisone 1 mg/kg/d for 30 days and progressive tapering of steroids, to get 0,5 mg/kg/d at M3 and 0,25 mg/kg/d at M6 and 5-10 mg at M12.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Ganglion Sphenopalatine Block Versus Placebo on Persistent Headache Following COVID-19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Moderate to severe headache (NRS \>= 3) with self reported duration of minimum 6 hours during the past week as well as moderate to severe headache (NRS \>= 3) on the day of intervention.~* Onset of headache during or maximum 4 weeks after PCR-verified COVID-19 infection.~* Headache must have persisted for at least 4 weeks following COVID-19 diagnosis.~Exclusion Criteria:~* Patients who cannot cooperate to the study~* Patients who does not understand or speak Danish~* Allergy to the drugs used in the study~* Has taken opioids within 12 hours prior to intervention~* History of migraine or persistent headache before COVID-19 infection.~* Active COVID-19 infection (defined by the Danish Goverment regulations, i.e. 48 hours after last symptoms (omitting long term effects) or 7 days after positive COVID-19 test if no symptoms.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ropivacaine-Lidocaine (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- Sham-block with Placebo (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pain in Traumatic Brain Injury - Basile, MD

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* documented history of traumatic brain injury~* 18 years or older~Exclusion Criteria:~* younger than 18 years old~* cannot read and write English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mid-Atlantic Research Group Single-Operator Cholangioscopic Assessment of Biliary Strictures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than or equal to 18 years~* Presence of indeterminate biliary strictures with clinical indications for ERCP. Strictures are considered indeterminate when evaluation including cross-sectional imaging is non-diagnostic. Patients who have previously undergone ERCP with sampling will be included, as well as those who have not previously undergone ERCP.~* Strictures located above the intrapancreatic bile duct~* The Subject's physician determines and ERCP is clinically indicated~* Able to provide informed consent~Exclusion Criteria:~* Prior enrollment in the study or another study evaluating biliary strictures~* Presence of extrahepatic malignancy or previously-diagnosed hepatocellular carcinoma~* Pregnancy~* At-risk populations including prisoners and mentally challenged~* Unwilling to provide informed consent~* Medically unfit to undergo ERCP~* History of liver transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Standard (Type: NO_INTERVENTION): Standard of care biopsies with optional SOC-directed biopsy afterwards
- Study (Type: EXPERIMENTAL): SOC-directed biopsies using the SpyGlass System plus standard of care biopsies

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Electrocardiogram in General Practice : the EGG Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient consulting one of the generalist practitioner investigators~* In doctor's office or at home, scheduled or not,~* During normal surgery hours or out-of-hours service,~* Whatever the reason for consultation,~* Aged 18 years or older,~* Having an indication of ElectroCardioGram (ECG) and/or request certificate of non-contra-indication to the practice of physical activity certificate of non-contra-indication to the practice of physical activity~Exclusion Criteria:~* ElectroCardioGram (ECG) not performed due to emergency context~* Patient with cognitive impairment who cannot give consent to participate in the study and / or patient under guardianship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patient with indication of ElectroCardioGram (ECG) (Type: None): Patient with indication of ElectroCardioGram (ECG) will be included. They will have a collection of results ElectroCardioGram (ECG).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with diagnosis of hepatic cell carcinoma (HCC) according to the AASLD- EASL criteria~* Age \>18 years~* Advanced stage of disease defined as HCC not eligible for locoregional treatments (ab initio or following progression after such treatments)~* Liver function classified as Child-Pugh class B~* ECOG performance status \< or = 2~* Life expectancy of at least 2 months~* Adequate contraception for fertile male and female patients~* Signed informed consent~Exclusion Criteria:~* Prior exposure to sorafenib or antiangiogenesis drugs~* Concomitant diseases that contraindicate the use of sorafenib~* Gastro-intestinal bleeding in the previous 30 days~* Altered renal function(creatinine \> 1.5 x ULN), or haematological function (platelet count \< 60 x 10\^9/L, hemoglobin \< 9 g/dl)~* Serious active infections (\> grade 2 CTCAE version 3.0)~* Congestive heart failure, history of congestive heart failure, unstable angina pectoris, myocardial infarct or significant valvular heart disease or uncontrolled heart arrhythmia~* Patients who are unable or unwilling to participate in the study~* Pregnant or lactating females~* Hepatic encephalopathy of any grade

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A: Best Supportive Care (Type: ACTIVE_COMPARATOR): best supportive care
- B: Sorafenib 400 mg, twice a day + Best Supportive Care (Type: EXPERIMENTAL): sorafenib + best supportive care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Per-operating Use of a Probe for Detection of β+

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \< 80 years old;~* Karnofsky index ≥80% ;~* Informed consent signed~* Patients with an indication of thoracic, visceral, or ENT surgery with the aim of a diagnostic biopsy, of an invasive minimal treatment, or an initial or complementary resection~Exclusion Criteria:~* Pregnancy~* Enable to sign informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 18F-FDG PET/CT (Type: EXPERIMENTAL): 18F-FDG radiotracer All patients will undergo a 18F-FDG PET/CT and a surgery with probe detection of β+''

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues